Aurinia Pharmaceuticals Inc. (AUPH) Stock
7 of the hedge funds AlphaScala tracks reported AUPH in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $34.69M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own AUPH?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 2.04M | $34.69M | +9% |
| Renaissance Technologies Jim Simons (founder) | 1.55M | $26.27M | -7% |
| D.E. Shaw David Shaw | 1.41M | $23.90M | -10% |
| Millennium Management Israel Englander | 244K | $4.15M | +109% |
| Citadel Ken Griffin | 241K | $4.08M | -12% |
| Hussman Investment Trust John Hussman | 210K | $3.56M | +150% |
| Blackstone | 16K | $270.7K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Aurinia Pharmaceuticals Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 10, 26 | Robertson Stephen P. | Chief Legal Officer | SELL | 11.9K | $190K |
| Aug 21, 26 | Robertson Stephen P. | Chief Legal Officer | SELL | 21.0K | $356K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →AUPH price chart
Powered by TradingViewWhat does Aurinia Pharmaceuticals Inc. do?
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases that have high unmet medical needs. Its flagship product, LUPKYNIS (voclosporin), serves as the first FDA-approved oral therapy for adult patients with active lupus nephritis, a serious kidney complication of lupus. The company also advances aritinercept, a dual inhibitor targeting B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), designed for potential use in various autoimmune conditions. Aurinia Pharmaceuticals Inc. engages in research, development, and commercialization within the biotechnology sector of healthcare, emphasizing innovative treatments to address gaps in patient care. It maintains collaborations, such as with Otsuka Pharmaceutical Co., Ltd., to support its therapeutic pipeline. Founded in 1993 and headquartered in Edmonton, Canada, Aurinia Pharmaceuticals Inc. plays a vital role in advancing oral and biologic therapies for autoimmune disorders, contributing to improved outcomes in rheumatology and nephrology.